1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6F7A731DB98B782E6002587AD004C4061
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/F7A731DB98B782E6002587AD004C4061?OpenDocument
18
19OpenDocument
2018.208.126.232
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Clinical Trials

Document Excerpt: Best Practices in the Management of Investigator Initiated Trials in Oncology: Structure, Activities and Responsibilities

DB Image

Excerpt in Cart

ID: MD-808


Features:

8 Info Graphics

21 Data Graphics

250+ Metrics

10 Narratives


Pages/Slides: 4


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt".

To return to the study abstract to purchase the full study -
click here

This excerpt includes research findings and metrics from document #5708 “Best Practices in the Management of Investigator Initiated Trials in Oncology: Structure, Activities and Responsibilities”.

Industries Profiled:
Medical Device; Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Becton Dickinson; Bayer; Cipla; Daiichi Sankyo; Eisai; EMD Serono; Guerbet; Ipsen; Jazz Pharmaceuticals; Karyopharm Therapeutics; Merck; Sandoz; Sanofi; Solidfarma; Takeda Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.